MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Guardant Health Inc

Closed

SectorHealthcare

48.04 -3.55

Overview

Share price change

24h

Current

Min

47.87

Max

49.71

Key metrics

By Trading Economics

Income

16M

-95M

Sales

1.7M

203M

Profit margin

-46.768

Employees

1,999

EBITDA

-12M

-111M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+21.97% upside

Dividends

By Dow Jones

Next Earnings

30 lip 2025

Market Stats

By TradingEconomics

Market Cap

333M

6.3B

Previous open

51.59

Previous close

48.04

News Sentiment

By Acuity

50%

50%

148 / 376 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Guardant Health Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 lip 2025, 22:07 UTC

Major Market Movers

Trade Desk Rises on S&P 500 Inclusion

14 lip 2025, 17:06 UTC

Major Market Movers

Crypto Assets Rally Ahead of Possible U.S. Legislation

14 lip 2025, 16:47 UTC

Acquisitions, Mergers, Takeovers

NatWest to Sell Stake in Permanent TSB

14 lip 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

14 lip 2025, 23:38 UTC

Market Talk

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14 lip 2025, 23:37 UTC

Market Talk

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14 lip 2025, 23:29 UTC

Market Talk

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14 lip 2025, 23:29 UTC

Market Talk

Global Energy Roundup: Market Talk

14 lip 2025, 23:02 UTC

Earnings

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14 lip 2025, 23:02 UTC

Earnings

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14 lip 2025, 23:02 UTC

Earnings

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14 lip 2025, 23:01 UTC

Earnings

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14 lip 2025, 23:01 UTC

Earnings

China Vanke Expects 1H Loss to Widen >000002.SZ

14 lip 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

14 lip 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 lip 2025, 20:07 UTC

Market Talk

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14 lip 2025, 20:05 UTC

Market Talk

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14 lip 2025, 19:11 UTC

Market Talk

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14 lip 2025, 19:09 UTC

Market Talk

Gold Breaks a 3-Day Win Streak -- Market Talk

14 lip 2025, 18:59 UTC

Market Talk

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14 lip 2025, 18:30 UTC

Acquisitions, Mergers, Takeovers

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14 lip 2025, 18:25 UTC

Market Talk

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14 lip 2025, 18:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 lip 2025, 16:59 UTC

Market Talk

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14 lip 2025, 16:53 UTC

Hot Stocks

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 lip 2025, 16:27 UTC

Market Talk

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14 lip 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

14 lip 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 lip 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 lip 2025, 16:12 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Peer Comparison

Price change

Guardant Health Inc Forecast

Price Target

By TipRanks

21.97% upside

12 Months Forecast

Average 61.29 USD  21.97%

High 70 USD

Low 56 USD

Based on 19 Wall Street analysts offering 12 month price targets forGuardant Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

19 ratings

19

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

38.86 / 47.41Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

148 / 376 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.